OssDsign strengthens patent coverage for OssDsign Cranial PSI in key market
OssDsign AB (publ) today announced that the United States Patent and Trademarks Office (USPTO) has issued a notice of allowance regarding the implant design for OssDsign Cranial PSI. With the allowance in USA, OssDsign strengthens the patent protection for the OssDsigns technology in the company’s most important market.
The patent was allowed in Europe and Japan last year and also in Australia earlier this year. With the allowance in USA, stronger patent protection for OssDsign Cranial PSI is now established in all key markets. The patent covers the implant, its support structure, as well as the method of making a custom implant through additive manufacturing. The additive manufacturing process provides a number of advantages, including rapid fabrication of customized implants for each patient, including various implant properties such as localized stiffness and/or localized flexibility, as well as the ability to fabricate implants with complex and/or irregular geometries (including complex curved surfaces).
The patent family, which is valid until 2035, adds to an extensive patent protection in Europe and US related both to implant design as well as the company’s material technology in the field of ceramic material formulations and their applications for medical use.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90
Erik Penser Bank AB is the company’s Certified Adviser.
Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: email@example.com.
OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.